Stay informed
MAPS practices the principle of Open Science, Open Books, transparently sharing what we learn. Through our publications, we seek to Be the Bridge, building common knowledge between the medical, the mystical, the marginalized, and the mainstream.
Sign Up for Our Newsletter:
Are you a member of the media? Visit our newsroom.
2026 First Quarter — Legislative Wrap Up
March 30, 2026
2026 is an important year for psychedelic state policy reform, reflecting the emerging evidence, creative leadership, and increasing confidence of a more mature movement. As the public deepens its understanding …
MAPS, in Partnership with the Shulgin Foundation, Launches Music Is the Bridge Video Series; First Episode Features Reggie Watts and Hamilton Morris
March 11, 2026
Lafayette, CA (March, 11, 2026) — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit advancing research, education, and advocacy around psychedelics and cannabis, …
MAPS Sends Expert Delegation to United Nations Commission on Narcotic Drugs
March 9, 2026
Vienna, Austria; March 9, 2026 —The Multidisciplinary Association for Psychedelic Studies (MAPS) will send senior academics, advocates, Veterans, and policy experts to the 69th session of the United …
In a Defining Election Year, MAPS Releases Policy Guidebook to Shape the Future of Psychedelic Reform
February 5, 2026
Washington, DC; February 4, 2026 — With the United States in a pivotal election year, the Multidisciplinary Association for Psychedelic Studies (MAPS) released its Policy Guidebook, a robust resource …
MAPS and Columbia University Partner on First-of-its-Kind Study of MDMA-Assisted Couples Therapy
February 3, 2026
February 2, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announces a formal research partnership with Columbia University to study how practitioners are facilitating MDMA-assisted …
MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study
January 30, 2026
On January 30, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted MJP2 Protocol Amendment 4, Version 1 (A4V1) to the U.S. Food and Drug Administration (FDA) for review. …
Green, Volat Transition from the MAPS Board of Directors to Committee Members
January 14, 2026
January 14, 2026 — In October 2025, Joe Green and Miriam Volat resigned their positions as members of the MAPS Board of Directors. Mr. Green joined the MAPS board in December 2020 and — among other …
MAPS Submits 2025 Cannabis Data Safety Update Report to FDA for MJP2 Phase 2 Study
January 13, 2026
On January 13, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted the 2025 Cannabis Data Safety Update Report (DSUR) to the U.S. Food and Drug Administration (FDA). The …
MAPS Supports Therapy Education for First-Ever Department of Defense-Affiliated MDMA-Assisted Therapy Pilot
December 23, 2025
December 23, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the completion of a therapy training initiative supporting clinicians participating in a Department of Defense …
Rescheduling Cannabis Doesn’t End Prohibition’s Harms…
December 18, 2025
The executive order to reschedule cannabis marks a symbolic victory and a recalibration of decades of federal misclassification. Reclassifying cannabis as a Schedule III substance is a long-overdue acknowledgment …
Ohio State’s Center for Psychedelic Drug Research and Education collaborates with MAPS for the Ohio P.E.A.C.E. program
November 17, 2025
Using funding provided by the Ohio Department of Behavioral Health, the Center for Psychedelic Drug Research and Education (CPDRE) will equip more than 127,000 Ohio professionals with skills in psychedelic …
MAPS and HoloMind Institute Host International MDMA-Assisted Therapy Training in Poland
October 8, 2025
San Jose, CA | October 6, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, is partnering …